{"title":"与编辑委员会成员见面","authors":"A. Carella","doi":"10.2174/1871529x2104211231145446","DOIUrl":null,"url":null,"abstract":"Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meet the Editorial Board Member\",\"authors\":\"A. Carella\",\"doi\":\"10.2174/1871529x2104211231145446\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.\",\"PeriodicalId\":93925,\"journal\":{\"name\":\"Cardiovascular & hematological disorders drug targets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular & hematological disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871529x2104211231145446\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529x2104211231145446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
自2008年以来,Fabian Kiessling教授一直领导德国亚琛工业大学Helmholtz生物医学工程研究所实验分子成像研究所。他的研究目标是开发新的诊断、治疗和治疗探针,以及先进的成像技术和图像分析工具。在此背景下,他的主要研究重点是血管和微环境组织特性的调查和诊断评估,以及探索其对疾病进展和治疗反应的影响。法比安·基斯林在德国海德堡大学学习医学,并完成了他的论文。直到2002年底,他一直在海德堡的德国癌症研究中心(DKFZ)放射科担任住院医师。2003年,他转到DKFZ放射医学物理系,担任分子成像组组长。同时,他在海德堡大学的不同部门接受了临床培训,并于2007年获得了委员会的放射科医师认证。2006年,法比安·基斯林(Fabian Kiessling)在实验放射学中进行了康复治疗。2008年,他与Matthias Braeutigam共同创立了invvivocontrast GmbH。费边·基斯林是400多篇科学出版物和书籍章节的作者,编辑了四本书,并获得了许多研究奖项,其中包括“埃米尔·萨尔泽癌症研究奖”和“里奇赞海恩奖”。此外,他于2019年被授予世界分子成像学会会员,并于2020年被Clarivate Analytics (Web of Science)确定为“高被引研究员”。他是欧洲放射学功能和分子成像学会(ESMOFIR)的创始成员,曾担任欧洲分子成像学会(ESMI)的财务主管和秘书,是ESMI“图像引导治疗和药物输送(IGTDD)”工作组的创始成员,并担任欧洲放射学会(ESR)“分子成像”小组委员会主席。此外,他还是世界分子成像学会董事会成员,并于2016年在纽约担任世界分子成像会议(WMIS)的项目主席。
Since 2008, Professor Dr. Fabian Kiessling has been leading the Institute of Experimental Molecular Imaging at the Helmholtz Institute for Biomedical Engineering at the RWTH-University in Aachen, Germany. The aim of his research is the development of novel diagnostic, theranostic and therapeutic probes as well as of advanced imaging technologies and image analysis tools. In this context, the main focus of his research is the investigation and diagnostic assessment of vascular and microenvironmental tissue properties and the exploration of its impact on disease progression and therapy response. Fabian Kiessling studied Medicine and did his thesis at the University in Heidelberg, Germany. Until the end of 2002, he worked as resident in the Department of Radiology at the German Cancer Research Center (DKFZ) in Heidelberg. In 2003, he moved to the Department of Medical Physics in Radiology of the DKFZ as leader of the Molecular Imaging group. In parallel, he did his clinical training at different departments of the University of Heidelberg and received the board certification as Radiologist in 2007. Fabian Kiessling did his habilitation in experimental radiology in 2006. In 2008, he founded the invivoContrast GmbH together with Matthias Braeutigam. Fabian Kiessling is author of more than 400 scientific publications and book chapters, has edited four books and received many research awards, among those are the “Emil Salzer Price for Cancer Research” and the “Richtzenhain Price”. Furthermore, he was awarded as Fellow of the World Molecular Imaging Society in 2019 and in 2020 was identified as “Highly Cited Researcher” by Clarivate Analytics (Web of Science). He is founding member of the European Society for Functional and Molecular Imaging in Radiology (ESMOFIR), has served as treasurer and secretary of the European Society for Molecular Imaging (ESMI), is founding member of the ESMI working group “Image Guided Therapy and Drug Delivery (IGTDD)”, and was chairman of the “Molecular Imaging” subcommittee of the European Society for Radiology (ESR). In addition, he is a member of the Board of Trustees of the World Molecular Imaging Society and was Program Chair of the World Molecular Imaging Conference (WMIS) in New York in 2016.